Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. Acute Pharmacological Inhibition of Protein Kinase R-Like Endoplasmic Reticulum Kinase Signaling After Spinal Cord Injury Spares Oligodendrocytes and Improves Locomotor Recovery

Acute Pharmacological Inhibition of Protein Kinase R-Like Endoplasmic Reticulum Kinase Signaling After Spinal Cord Injury Spares Oligodendrocytes and Improves Locomotor Recovery

Journal of Neurotrauma, 2023 · DOI: 10.1089/neu.2022.0177 · Published: May 1, 2023

Spinal Cord InjuryNeurologyGenetics

Simple Explanation

This study investigates the role of PERK, a protein involved in cellular stress response, after spinal cord injury (SCI) in mice. The researchers found that inhibiting PERK shortly after SCI improved the recovery of movement and reduced damage to white matter in the spinal cord. The study suggests that excessive activation of PERK after SCI contributes to white matter damage. The scientists observed increased numbers of oligodendrocytes, cells critical for nerve insulation, in mice treated with a PERK inhibitor called GSK2656157. In laboratory experiments, GSK2656157 protected oligodendrocyte precursor cells from stress-induced damage. This suggests that targeting PERK could be a potential therapeutic strategy to protect the central nervous system after acute injuries like SCI.

Study Duration
6 Weeks
Participants
WT C57Bl/6 female mice (6–8 weeks old)
Evidence Level
Not specified

Key Findings

  • 1
    Acute inhibition of PERK with GSK2656157 after SCI reduced ER stress, improved white matter sparing, and enhanced hindlimb locomotion recovery in mice.
  • 2
    GSK2656157 treatment increased the number of oligodendrocytes at the injury epicenter, suggesting a protective effect on these cells.
  • 3
    In vitro, GSK2656157 protected primary mouse oligodendrocyte precursor cells from ER stress-induced cytotoxicity.

Research Summary

This study demonstrates that acute pharmacological inhibition of PERK signaling after SCI spares oligodendrocytes and improves locomotor recovery in mice. The findings suggest that excessive acute activation of PERK contributes to white matter damage. GSK2656157, a PERK inhibitor, reduced ER stress, increased oligodendrocyte numbers, and protected oligodendrocyte precursor cells from ER stress-induced cytotoxicity. These results suggest that GSK2656157 has a protective effect on oligodendrocytes. Pharmacological inhibition of PERK is a potential strategy to protect central nervous system white matter following acute injuries, including SCI. Therefore, PERK inhibition is a potential therapeutic target in CNS trauma.

Practical Implications

Therapeutic Potential

Pharmacological inhibition of PERK represents a potential therapeutic target in CNS trauma.

Clinical Relevance

Oral administration of GSK2656157 may allow contused mice to recover from some coordination to mostly coordinated weight bearing and plantar stepping.

Further Research

Identify novel therapeutics that can effectively modulate PERK signaling without major toxic side effects.

Study Limitations

  • 1
    GSK2656157 may have off-target effects, such as inhibiting RIPK1.
  • 2
    The study only examined acute inhibition of PERK; chronic inhibition may have different effects.
  • 3
    The study was conducted in mice; results may not translate directly to humans.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury